Salt and Aldosterone - Reciprocal and Combined Effects in Preclinical Models and Humans

Horm Metab Res. 2024 Jan;56(1):99-106. doi: 10.1055/a-2172-7228. Epub 2023 Sep 8.

Abstract

Primary aldosteronism is an endocrine disorder caused by excessive production of aldosterone by the adrenal glands, and is recognized as the most important cause of endocrine hypertension. With specific therapy, this type of hypertension is potentially curable. In the general population, high salt intake increases the risk for cardiovascular diseases like stroke. In populations with aldosterone excess, observational and experimental data suggest that aldosterone-induced organ damage requires a combination of high dietary salt intake and high plasma aldosterone, i.e., plasma aldosterone levels inappropriately high for salt status. Therefore, understanding the relationship between plasma aldosterone levels and dietary salt intake and the nature of their combined effects is crucial for developing effective prevention and treatment strategies. In this review, we present an update on findings about primary aldosteronism and salt intake and the underlying mechanisms governing their interaction.

Publication types

  • Review

MeSH terms

  • Aldosterone
  • Cardiovascular Diseases* / etiology
  • Humans
  • Hyperaldosteronism* / complications
  • Hypertension* / complications
  • Sodium Chloride, Dietary / adverse effects

Substances

  • Aldosterone
  • Sodium Chloride, Dietary

Grants and funding

Funding Information This work was supported by the Else Kröner-Fresenius Stiftung in support of the German Conn’s Registry-Else-Kröner Hyperaldosteronism Registry (2013_A182, 2015_A171 and 2019_A104 to MR), the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No. 694913 to MR), by the Deutsche Forschungsgemeinschaft (DFG) within the CRC/Transregio 205/2, (project No. 314061271) “The Adrenal: Central Relay in Health and Disease” to CA, HS, and MR and within the Clinician Scientist Program In Vascular MEdicine (PRIME) MA 2186/14-1 to HS, by the Förderprogramm für Forschung und Lehre (FöFoLe) Reg.-Nr 1051 to CA and by grants from the China Scholarship Council(CSC) — 202106940008 to LC.